Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Is Continuous or Intermittent Chemotherapy More Beneficial in Stage 4 Breast Cancer?

Is Continuous or Intermittent Chemotherapy More Beneficial in Stage 4 Breast Cancer?

At the European Society for Medical Oncology (ESMO) 2019 Breast Cancer Congress, analyses of the Stop & Go study showed that continuous chemotherapy provided greater benefit than intermittent treatment in advanced breast cancer, both increasing survival and preserving quality of life.

A phase-III clinical trial , Stop & Go assigned patients with HER2 -negative breast cancer, totaling 420 patients, to an intermittent chemotherapy schedule (4 cycles, then a “treatment holiday,” then another 4 cycles) or a continuous schedule with the same 8 cycles given consecutively. Both arms received first-line “paclitaxel plus bevacizumab” and second-line “capecitabine or liposomal doxorubicin.”

Survival results

Frans Erdkamp of Zuyderland Medical Center in the Netherlands presented findings on the survival benefits of continuous chemotherapy compared with intermittent treatment in both first- and second-line chemotherapy. “Although our main focus in this analysis was on second-line treatment effectiveness, interestingly, updated overall survival results showed better survival with continuous treatment for all patients, including first-line treatment,” he said.

comparison of patients receiving intermittent and continuous chemotherapy for advanced breast cancer
  • The 270 patients receiving second-line treatment were divided into two arms: 131 received intermittent and 139 continuous chemotherapy. Progression-free survival was 3.5 months with intermittent treatment and 5 months with continuous treatment (HR 1.04, CI= 0.69–1.57).
  • Median progression-free survival across both first and second lines was 14.6 months for intermittent treatment and 16.6 months for continuous treatment. 
  • Median overall survival for the entire patient group was 20.3 months with intermittent treatment and 23 months with continuous treatment (HR: 1.93, CI= 1.26–2.95).

Quality-of-life results

The study’s quality of life results were presented by Anouk Claessens. “In clinical practice, we see important differences in treatment strategies, so we thought a trial investigating the effect of scheduling with modern agents on quality of life would be useful,” she said. Dr. Claessens noted that, at the start of the study, they had thought treatment holidays would benefit quality of life.

Quality of life was measured every 12 weeks during treatment and follow-up. The trajectories of both physical and mental quality-of-life scores were tracked for each scheduling arm, and differences in trajectories between arms were estimated. Median follow-up was 11.3 months.

“We saw a linear decline in physical quality-of-life scores in the intermittent treatment arm,” said Dr. Claessens, adding: “Comparing the quality-of-life trajectories between treatment arms showed that the maximum differences were not statistically significant, but there was a trend toward more favorable scores in the continuous treatment arm.”

Researcher Monique Bos of Erasmus University Medical Center in the Netherlands said: “We were somewhat surprised by these quality-of-life results, which contradicted our hypothesis. When explaining treatment schedules to patients, we tend to suggest that a ‘holiday,’ by the nature of the word, might be beneficial, but that was not the case.” she said.

Comment

This study provides meaningful answers to a question encountered very often in clinical practice: our patients with advanced breast cancer ask why uninterrupted treatment is recommended. Until now, based on evidence from chemotherapy regimens no longer in use, we knew that in metastatic (advanced) breast cancer, continuous chemotherapy was better. Both the survival and quality-of-life data from this new Stop & Go study, consistent with previous international treatment guideline recommendations, support giving preferably single-agent chemotherapy (at least after first-line treatment) continuously for as long as the patient tolerates it and it remains effective. The finding that continuous chemotherapy was in no way associated with worse quality of life is also highly meaningful and emphasizes the importance of our advanced breast cancer patients choosing continuous chemotherapy.

Sources

Stop&Go study presented by Erdkamp et al and Claessens et al at the European Society for Medical Oncology (ESMO) Breast Cancer Congress 2019 (Abstracts 158P_PR and 159P_PR)

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Is Continuous or Intermittent Chemotherapy More Beneficial in Stage 4 Breast Cancer?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy